Latest clinical trials are testing new TCRs that recognize a broad array of cancer antigens such as p53, gp100, carcinoembryonic antigen and the NY-ESO-1 antigen of the cancer testis [57–59], which may enable targeting of other cancer types in addition to melanoma. Here, PMEL is linked to cancer.